Moxifloxacin Pharmathen (Moxifloxacin Hydrochloride)

Moxifloxacin blocks bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA replication and transcription. By stabilizing the enzyme‑DNA complex, it prevents DNA strand resealing, leading to bacterial cell death. This mechanism provides bactericidal activity against many common pathogens.

The specific dose and treatment duration are determined by the prescribing clinician based on the infection type, severity, patient age, renal function, and other clinical factors. Healthcare professionals should follow local prescribing guidelines and adjust therapy as needed.

The safety of moxifloxacin in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with older fluoroquinolones such as ciprofloxacin. It also has a once‑daily dosing regimen, which can improve adherence, but it shares class‑related safety considerations like QT prolongation and tendon toxicity.

Store at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Moxifloxacin Pharmathen is administered orally, typically as a tablet taken with a full glass of water. It may be taken with or without food, but patients should avoid concurrent intake of antacids containing magnesium or aluminum, which can reduce absorption.

Serious risks include tendon rupture, QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatic toxicity, and rare skin reactions like Stevens‑Johnson syndrome. Patients should be educated to report any sudden tendon pain, palpitations, or severe skin changes promptly.

Moxifloxacin should be avoided in individuals with a known hypersensitivity to fluoroquinolones, those with a history of tendon disorders related to quinolone use, patients with prolonged QT interval, and anyone taking other medications that significantly prolong QT. Caution is also advised for patients with severe renal impairment.